APO Research
Talk to an analyst

APO RESEARCH · REPORT

C5 Complement Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global C5 Complement Inhibitor Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchC5 Complement Inhibitor Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal C5 Complement Inhibitor Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal C5 Complement Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C5 Complement Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal C5 Complement Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global C5 Complement Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for C5 Complement Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for C5 Complement Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for C5 Complement Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the C5 Complement Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the C5 Complement Inhibitor market include Alexion. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global C5 Complement Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of C5 Complement Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents C5 Complement Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the C5 Complement Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

C5 Complement Inhibitor Segment by Company

Alexion

C5 Complement Inhibitor Segment by Type

Eculizumab

Raflizumab

C5 Complement Inhibitor Segment by Application

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Atypical Hemolytic Uremic Syndrome (aHUS)

Other

C5 Complement Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global C5 Complement Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions C5 Complement Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify C5 Complement Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze C5 Complement Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C5 Complement Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C5 Complement Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C5 Complement Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the C5 Complement Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global C5 Complement Inhibitor industry.

Chapter 3: Detailed analysis of C5 Complement Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of C5 Complement Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of C5 Complement Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. C5 Complement Inhibitor Industry Trends Table 2. C5 Complement Inhibitor Industry Drivers Table 3. C5 Complement Inhibitor Industry Opportunities and Challenges Table 4. C5 Complement Inhibitor Industry Restraints Table 5. Global C5 Complement Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global C5 Complement Inhibitor Revenue Share by Company (2021-2026) Table 7. Global C5 Complement Inhibitor Sales Volume by Company (k units) & (2021-2026) Table 8. Global C5 Complement Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global C5 Complement Inhibitor Average Price (US$/unit) of Company (2021-2026) Table 10. Global C5 Complement Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global C5 Complement Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global C5 Complement Inhibitor Company, Product Type & Application Table 13. Global C5 Complement Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global C5 Complement Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Eculizumab Table 18. Significant Companies of Raflizumab Table 19. Global C5 Complement Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global C5 Complement Inhibitor Sales Volume by Type (2021-2026) & (k units) Table 21. Global C5 Complement Inhibitor Sales Volume by Type (2027-2032) & (k units) Table 22. Global C5 Complement Inhibitor Sales Volume Share by Type (2021-2026) Table 23. Global C5 Complement Inhibitor Sales Volume Share by Type (2027-2032) Table 24. Global C5 Complement Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global C5 Complement Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global C5 Complement Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global C5 Complement Inhibitor Sales Value Share by Type (2021-2026) Table 28. Global C5 Complement Inhibitor Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 30. Significant Companies of Atypical Hemolytic Uremic Syndrome (aHUS) Table 31. Significant Companies of Other Table 32. Global C5 Complement Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global C5 Complement Inhibitor Sales Volume by Application (2021-2026) & (k units) Table 34. Global C5 Complement Inhibitor Sales Volume by Application (2027-2032) & (k units) Table 35. Global C5 Complement Inhibitor Sales Volume Share by Application (2021-2026) Table 36. Global C5 Complement Inhibitor Sales Volume Share by Application (2027-2032) Table 37. Global C5 Complement Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global C5 Complement Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global C5 Complement Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global C5 Complement Inhibitor Sales Value Share by Application (2021-2026) Table 41. Global C5 Complement Inhibitor Sales Value Share by Application (2027-2032) Table 42. Global C5 Complement Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global C5 Complement Inhibitor Sales by Region (2021-2026) & (k units) Table 44. Global C5 Complement Inhibitor Sales Market Share by Region (2021-2026) Table 45. Global C5 Complement Inhibitor Sales by Region (2027-2032) & (k units) Table 46. Global C5 Complement Inhibitor Sales Market Share by Region (2027-2032) Table 47. Global C5 Complement Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global C5 Complement Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global C5 Complement Inhibitor Sales Value Share by Region (2021-2026) Table 50. Global C5 Complement Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global C5 Complement Inhibitor Sales Value Share by Region (2027-2032) Table 52. Global C5 Complement Inhibitor Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global C5 Complement Inhibitor Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global C5 Complement Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global C5 Complement Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global C5 Complement Inhibitor Sales by Country (2021-2026) & (k units) Table 57. Global C5 Complement Inhibitor Sales Market Share by Country (2021-2026) Table 58. Global C5 Complement Inhibitor Sales by Country (2027-2032) & (k units) Table 59. Global C5 Complement Inhibitor Sales Market Share by Country (2027-2032) Table 60. Global C5 Complement Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global C5 Complement Inhibitor Sales Value Market Share by Country (2021-2026) Table 62. Global C5 Complement Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global C5 Complement Inhibitor Sales Value Market Share by Country (2027-2032) Table 64. Alexion Company Information Table 65. Alexion Business Overview Table 66. Alexion C5 Complement Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Alexion C5 Complement Inhibitor Product Portfolio Table 68. Alexion Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. C5 Complement Inhibitor Distributors List Table 72. C5 Complement Inhibitor Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. C5 Complement Inhibitor Product Image Figure 2. Global C5 Complement Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global C5 Complement Inhibitor Sales (2021-2032) & (k units) Figure 5. Global C5 Complement Inhibitor Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global C5 Complement Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Eculizumab Image Figure 10. Raflizumab Image Figure 11. Global C5 Complement Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global C5 Complement Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global C5 Complement Inhibitor Sales Volume Share by Type (2021-2032) Figure 14. Global C5 Complement Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global C5 Complement Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global C5 Complement Inhibitor Sales Value Share by Type (2021-2032) Figure 17. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 18. Atypical Hemolytic Uremic Syndrome (aHUS) Image Figure 19. Other Image Figure 20. Global C5 Complement Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global C5 Complement Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global C5 Complement Inhibitor Sales Volume Share by Application (2021-2032) Figure 23. Global C5 Complement Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global C5 Complement Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global C5 Complement Inhibitor Sales Value Share by Application (2021-2032) Figure 26. Global C5 Complement Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global C5 Complement Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global C5 Complement Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global C5 Complement Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 31. North America C5 Complement Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 33. Europe C5 Complement Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific C5 Complement Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 37. South America C5 Complement Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa C5 Complement Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa C5 Complement Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt C5 Complement Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. C5 Complement Inhibitor Value Chain Figure 125. Manufacturing Cost Structure Figure 126. C5 Complement Inhibitor Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Eculizumab
  • Raflizumab
Applications
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Other
Companies covered
  • Alexion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global C5 Complement Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global C5 Complement Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global C5 Complement Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 C5 Complement Inhibitor Market Dynamics
  1. 2.1 C5 Complement Inhibitor Industry Trends
  2. 2.2 C5 Complement Inhibitor Industry Drivers
  3. 2.3 C5 Complement Inhibitor Industry Opportunities and Challenges
  4. 2.4 C5 Complement Inhibitor Industry Restraints
3 C5 Complement Inhibitor Market by Company
  1. 3.1 Global C5 Complement Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global C5 Complement Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global C5 Complement Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global C5 Complement Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global C5 Complement Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global C5 Complement Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global C5 Complement Inhibitor Company Product Type and Application
  8. 3.8 Global C5 Complement Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global C5 Complement Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 C5 Complement Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 C5 Complement Inhibitor Market by Type
  1. 4.1 C5 Complement Inhibitor Type Introduction
  2. 4.1.1 Eculizumab
  3. 4.1.2 Raflizumab
  4. 4.2 Global C5 Complement Inhibitor Sales Volume by Type
  5. 4.2.1 Global C5 Complement Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global C5 Complement Inhibitor Sales Volume by Type (2021-2032)
  7. 4.2.3 Global C5 Complement Inhibitor Sales Volume Share by Type (2021-2032)
  8. 4.3 Global C5 Complement Inhibitor Sales Value by Type
  9. 4.3.1 Global C5 Complement Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global C5 Complement Inhibitor Sales Value by Type (2021-2032)
  11. 4.3.3 Global C5 Complement Inhibitor Sales Value Share by Type (2021-2032)
5 C5 Complement Inhibitor Market by Application
  1. 5.1 C5 Complement Inhibitor Application Introduction
  2. 5.1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  3. 5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  4. 5.1.3 Other
  5. 5.2 Global C5 Complement Inhibitor Sales Volume by Application
  6. 5.2.1 Global C5 Complement Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global C5 Complement Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global C5 Complement Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global C5 Complement Inhibitor Sales Value by Application
  10. 5.3.1 Global C5 Complement Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global C5 Complement Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global C5 Complement Inhibitor Sales Value Share by Application (2021-2032)
6 C5 Complement Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global C5 Complement Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global C5 Complement Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global C5 Complement Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global C5 Complement Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global C5 Complement Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global C5 Complement Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global C5 Complement Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global C5 Complement Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global C5 Complement Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America C5 Complement Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America C5 Complement Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe C5 Complement Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe C5 Complement Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific C5 Complement Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific C5 Complement Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America C5 Complement Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America C5 Complement Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa C5 Complement Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa C5 Complement Inhibitor Sales Value Share by Country, 2025 VS 2032
7 C5 Complement Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global C5 Complement Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global C5 Complement Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global C5 Complement Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global C5 Complement Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global C5 Complement Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global C5 Complement Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global C5 Complement Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global C5 Complement Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt C5 Complement Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt C5 Complement Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt C5 Complement Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion
  2. 8.1.1 Alexion Company Information
  3. 8.1.2 Alexion Business Overview
  4. 8.1.3 Alexion C5 Complement Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alexion C5 Complement Inhibitor Product Portfolio
  6. 8.1.5 Alexion Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 C5 Complement Inhibitor Value Chain Analysis
  2. 9.1.1 C5 Complement Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 C5 Complement Inhibitor Sales Mode & Process
  6. 9.2 C5 Complement Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 C5 Complement Inhibitor Distributors
  9. 9.2.3 C5 Complement Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst